Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertzye for PEI in Unresectable Pancreatic Cancer
NCT02985801Phase 2Terminated
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pancrelipase in exocrine pancreatic insufficiency (EPI) (2 arms). Primary endpoint: Change in Body Weight at 10 weeks. Started Dec 2016; status: terminated.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT02985801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985801.